CTLA4 and neoplasm: Recent years have been associated with striking success in tumor immunotherapy, especially checkpoint inhibitors that target programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) [6].